Summary of BioSig Technologies, Inc. Business Development Update Conference Call Company Overview - **Company**: BioSig Technologies, Inc. (OTCQB: BSGM) - **Date of Call**: November 18, 2020 - **Participants**: - Ken Londoner - Chairman and CEO - Andy Ballou - Vice President of Investor Relations - Other participants from Laidlaw & Company, Plum Tree Consulting, and JJK Consulting Key Points Industry and Business Updates - **Core Business**: Focus on the PURE EP System installations and commercialization outlook [4][12] - **ViralClear Subsidiary**: - Phase 2 clinical trial for merimepodib halted based on Safety Monitoring Committee's recommendation [7] - Operations winding down, with cash proceeds redirected to NeuroClear neuro technology program [9][11] - Engaging with three pharmaceutical/biotech companies for potential partnerships [10] Financial Performance - **Cash Position**: $32.7 million on the balance sheet, sufficient to support operations through 2021 and into 2022 [24] - **Burn Rate**: Approximately $1.4 million per month for the PURE EP business, with a total burn of $6.2 million in Q3 2020 [24][29] - **Commercial Inventory**: 65 units of commercial inventory already paid for, expected to generate revenue over the next 12 months [25] PURE EP System Progress - **Installations**: - Total of six installations completed, with plans for two additional installations [12][15] - Positive feedback from physicians using the system, with 363 total procedures performed year-to-date [13][14] - **Clinical Data**: - 35.5% of cases showed BioSig signals had more visible components compared to traditional systems [17] - Ongoing collection of clinical data to support future studies and marketing efforts [19][66] Market Strategy and Future Plans - **Expansion Plans**: - Targeting 12 to 16 hospitals for limited market release, with a focus on Northeast, Florida, and Texas regions in 2021 [20][21] - Plans to recruit additional sales and marketing personnel to support expansion [21] - **Commercial Transactions**: Expecting first commercial transaction in Q4 2020, with visibility for more based on successful installations [22] Challenges and Considerations - **COVID-19 Impact**: The pandemic has affected installation timelines, with some installations pushed to Q1 2021 [15][49] - **ViralClear Investments**: Investors in ViralClear will hold a stake in the NeuroClear program as the company seeks to create value from these assets [52] Additional Insights - **User Feedback**: Positive user feedback has led to software upgrades planned for early 2021 [33] - **Revenue Model**: Revenue will be generated from hardware sales, service contracts, and software upgrades [56][60] - **Clinical Trials**: Plans for investigator-initiated clinical trials to further validate the efficacy of the PURE EP system [66] Conclusion - BioSig Technologies is making significant progress in the commercialization of its PURE EP System, with a strong financial position and positive feedback from early adopters. The company is strategically planning for expansion and is optimistic about future growth despite challenges posed by the COVID-19 pandemic.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38659 BIOSIG TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 26-4333375 (State or other jurisdict ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share BSGM The NASDAQ Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ...

Corporate Presentation Spring 2020 S Y M BOL : BSG M 1 NASDAQ : BSGM Disclaimer This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, approvals and launches by BioSig of new products, market acceptance of BioSig's products, market and procedure projections, financing plans, and related documents. Forward-looking state ...

Start Time: 11:00 January 1, 0000 11:47 AM ET BioSig Technologies, Inc. (OTCQB:BSGM) Special Call June 09, 2020, 11:00 AM ET Company Participants Ken Londoner - Chairman and CEO, BioSig Technologies Nick Spring - CEO, ViralClear Pharmaceuticals Steve King - COO, ViralClear pharmaceuticals Jerry Zeldis - Executive Chair, ViralClear Pharmaceuticals Andrew Ballou - VP, IR Conference Call Participants Yale Jen - Laidlaw & Company Scott Henry - ROTH Capital Gary Zwetchkenbaum - Plum Tree Consulting Todd Ammons - ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38659 BIOSIG TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 26-4333375 (State or other jurisdiction ...

Summary of BioSig Technologies, Inc. and ViralClear Pharmaceuticals Conference Call Company and Industry Overview - **Company**: BioSig Technologies, Inc. (OTCQB: BSGM) and its subsidiary ViralClear Pharmaceuticals - **Industry**: Pharmaceutical industry focusing on antiviral drug development, particularly in response to COVID-19 Key Points and Arguments 1. **Introduction of ViralClear**: BioSig is focusing on its new subsidiary, ViralClear, which is developing the drug candidate Vicromax for treating COVID-19. Vicromax was previously developed for chronic hepatitis C and has shown promise against COVID-19 in preclinical tests [9][10][11]. 2. **Funding and Spin-off Plans**: BioSig has secured over $12 million in cash and plans to fund ViralClear through direct investments rather than selling BioSig stock. The intention is to spin off ViralClear into a public entity on NASDAQ, allowing BioSig shareholders to retain ownership in the new company [12][11]. 3. **Drug Development Timeline**: ViralClear aims to file an Investigational New Drug (IND) application soon, with human trials expected to start in May 2020. If successful, pivotal phase development could occur over the summer [21][20]. 4. **Mechanism of Action**: Vicromax (MMPD) targets RNA-dependent RNA polymerase and has shown activity against various RNA viruses, including SARS-CoV-2. The drug's mechanism involves inhibiting an enzyme crucial for viral replication, potentially preventing the emergence of resistant viral strains [27][60][31]. 5. **Collaboration with Mayo Clinic**: Dr. Andrew Badley from the Mayo Clinic is involved in overseeing the clinical trials for MMPD. The Mayo Clinic is considering a financial investment in ViralClear, indicating a strong partnership [24][26]. 6. **Market Positioning**: The company does not view other antiviral candidates as direct competition but rather as potential collaborators for combination therapies. This approach aims to reduce the risk of viral resistance [42][50]. 7. **Regulatory Environment**: The FDA has established a task force to expedite the review of drugs for COVID-19, which may facilitate a faster path to market for ViralClear's products [67][66]. 8. **Commercial Strategy**: ViralClear plans to utilize a virtual drug development model, contracting manufacturing resources in the U.S. and Europe to ensure supply for clinical and commercial needs [34][33]. Additional Important Information - **Intellectual Property**: ViralClear possesses a robust intellectual property portfolio, which is crucial for its competitive positioning in the market [21]. - **Clinical Trial Design**: The trials will focus on various endpoints, including viral load and clinical symptoms, to assess the drug's efficacy [75][74]. - **Future Outlook**: The company sees potential for MMPD to be stockpiled for future pandemics, emphasizing its long-term business viability beyond the current crisis [88][89]. This summary encapsulates the critical aspects of the conference call, highlighting the strategic direction of BioSig Technologies and its subsidiary ViralClear in the context of antiviral drug development amidst the COVID-19 pandemic.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2019 Commission File Number 001-38659 BIOSIG TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 26-4333375 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 54 Wilton Road, 2nd Floor Westport, CT 409-5444 (Address of principal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38659 BIOSIG TECHNOLOGIES, INC. (Exact name of registrant as specified in its charter) Delaware 26-4333375 (State or other jurisdict ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |----------------------------------------------------------------------------|-----------------------------------------|----------------------------------------------------------- ...